Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | CA7 | P43166 | 1/20 | 0.57 |
| ▸ | CTSK | P43235 | 11/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CTSS | P25774 | 4/20 | 0.47 |
| ▸ | CTSL | P07711 | 2/20 | 0.45 |
| ▸ | CTSB | P07858 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL9235390 | 0.98 | CA1 (0.55) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL4821105 | 0.91 | CA1 (0.50) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL24069882 | 0.85 | CA1 (0.57) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL22979292 | 0.85 | KMT2A (0.49) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL18086766 | 0.85 | KMT2A (0.49) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL305895 | 0.83 | CA1 (0.55) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL2550753 | 0.83 | CA1 (0.55) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL7148686 | 0.83 | CA1 (0.55) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL21676408 | 0.82 | CTSK (0.62) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL1303375 | 0.81 | CA1 (0.53) | CA1CA2CA7CTSKCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 410 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2903979-B1 | NOVEL COMPOUNDS, THEIR PREPARATION AND THEIR USES | INHIBIKASE THERAPEUTICS INC (US) | 2020-08-19 | — | — | EP | claimed |
| CN-102584937-A | Crystal forms of (3r)-1-(2-methylalanyl-d-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide | HELSINN THERAPEUTICS US INC | 2012-07-18 | — | — | CN | claimed |
| US-20090227618-A2 | Carboline Derivatives Useful in the Inhibition of Angiogenesis | PTC THERAPEUTICS, INC. (US) | 2009-09-10 | — | — | US | claimed |
| US-20070281962-A2 | Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration | PCT THERAPEUTICS, INC. (US) | 2007-12-06 | — | — | US | claimed |
| WO-2005089764-A9 | CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS | PTC THERAPEUTICS INC (US) | 2007-09-13 | — | — | WO | claimed |
| EP-1737461-A1 | CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS | PTC Therapeutics, Inc. (US) | 2007-01-03 | — | — | EP | claimed |
| US-20050272759-A1 | Carboline derivatives useful in the inhibition of angiogenesis | PTC THERAPEUTICS, INC. | 2005-12-08 | — | — | US | claimed |
| US-6967216-B2 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor | ASTRAZENECA AB (SE) | 2005-11-22 | — | — | US | claimed |
| WO-2005089764-A1 | CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS | PTC THERAPEUTICS, INC. (US) | 2005-09-29 | — | — | WO | claimed |
| EP-1140895-B1 | THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP | FUJISAWA PHARMACEUTICAL CO (JP) | 2004-03-24 | — | — | EP | claimed |
| US-20030225097-A1 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by np y5 receptor | ASTRAZENECA AB (SE) | 2003-12-04 | — | — | US | claimed |
| EP-1278739-A1 | AMINO SUBSTITUTED DIBENZOTHIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS MEDIATED BY THE NP Y5 RECEPTOR | AstraZeneca AB (SE) | 2003-01-29 | — | — | EP | claimed |
| US-6376548-B1 | FUNGICIDES; HERBICIDES; INSECTICIDES | ROHM AND HAAS COMPANY | 2002-04-23 | — | — | US | claimed |
| WO-2001085714-A1 | AMINO SUBSTITUTED DIBENZOTHIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS MEDIATED BY THE NP Y5 RECEPTOR | ASTRAZENECA AB (SE) | 2001-11-15 | — | — | WO | claimed |
| EP-1140895-A2 | THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-10-10 | — | — | EP | claimed |
| WO-2000040576-A2 | THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-13 | — | — | WO | claimed |
| CN-119302960-A | Unit dose compositions of AKT inhibitors | 南京正大天晴制药有限公司 | 2025-01-14 | — | — | CN | disclosed |
| CN-115916350-B | Unit dose compositions of AKT inhibitors | 南京正大天晴制药有限公司 | 2024-11-05 | — | — | CN | disclosed |
| US-5861429-A | MITICIDES AND ANTHELMINTICS | SANKYO COMPANY, LIMITED (JP) | 1999-01-19 | — | — | US | disclosed |
| WO-1998040421-A1 | CATIONIC GROUP 13 COMPLEXES INCORPORATING BIDENTATE LIGANDS AS POLYMERIZATION CATALYSTS | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 1998-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227618-A2 | Carboline Derivatives Useful in the Inhibition of Angiogenesis | VEGFA, FLT4, KDR | CA1 3943/4885CA2 875/4885CA7 876/4885 |
| US-20030225097-A1 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by np y5 receptor | NPY5R, NPY1R, NPY2R | CA1 2586/4885CA2 2486/4885CA7 3611/4885 |
| US-20050272759-A1 | Carboline derivatives useful in the inhibition of angiogenesis | VEGFA, FLT4, KDR | CA1 3943/4885CA2 875/4885CA7 876/4885 |
| US-20070281962-A2 | Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration | VEGFA, FLT4, MIF | CA1 4844/4885CA2 4487/4885CA7 4692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.